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Summary Cytochrome P450-dependent oxidation is a pathway for all-trans-retinoic acid (all-trans-RA) catabolism. Induction of this catabolic
pathway was studied in MCF-7 breast cancer cells. MCF-7 cells showed low constitutive all-trans-RA catabolism. Concentration-dependent
induction was obtained by preincubation of the cells with all-trans-RA (10-9 to 10-6 M). Onset of induction was fast, being detectable within
60 min, with maximal induction (45-fold) obtained after 16 h. Enzymatic characterization of induced all-trans-RA catabolism showed an
estimated Km value (Michaelis-Menten constant) of 0.33 RM and aVmax value (maximal velocity of an enzyme-catalysed reaction) of 54.5 fmol
polar all-trans-RA metabolites 106 cells-' h-1. These kinetic parameters represent the overall formation of polar metabolites from all-trans-RA.
Induction of all-trans-RA catabolism was also obtained with other retinoids, CH55 >> 13-cis-RA = all-trans-RA > 9-cis-RA >4-keto-all-trans-RA
>4-keto-13-cis-RA > retinol. The potency ofthe retinoids to induce all-trans-RA catabolism was correlated totheir retinoic acid receptor affinity
(Crettaz et al, 1990; Repa et al, 1990; Sani et al, 1990). Induction of all-trans-RA catabolism was inhibited by actinomycin D. Furthermore,
all-trans-RA did not increase cytosolic retinoic acid-binding protein (CRABP) mRNA levels. These data suggest that induction of all-trans-RA
catabolism in MCF-7 cells is a retinoic acid receptor-mediated gene transcriptional event. Induced all-trans-RA catabolism was inhibited by
various retinoids with decreasing potency in the order: all-trans-RA > 4-keto-all-trans-RA > 13-cis-RA > 9-cis-RA > 4-keto-13-cis-RA > retinol
> CH55. The antitumoral compound liarozole-fumarate inhibited all-trans-RA catabolism with a potency similar to that of all-trans-RA.
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Retinoids can modulate the growth and differentiation of various
normal and malignant cells in culture (Sporn and Roberts, 1983).
Retinol is the major circulating retinoid in the human body (Ong
and Chytil, 1983; Wolf, 1984). All-trans-retinoic acid (all-trans-
RA) is an endogenous metabolite of retinol (McCormick and
Napoli, 1982) which has proven to be more potent than retinol in
a variety of in vivo and in vitro assay systems. All-trans-RA
exhibits antiproliferative and differentiation-inducing activity in in
vitro cultures of cells from established lines, such as P19 and F9
embryonal carcinoma cells (Strickland and Mahdavi, 1978; Jones-
Villeneuve et al, 1982), melanoma cells (Lotan and Lotan, 1981),
HL-60 (Matsushima et al, 1992) and U937 leukaemia cells (Ho,
1985). Clinically, all-trans-RA has been proven to be a successful
form of treatment for squamous carcinomas and acute promyelo-
cytic leukaemia (Parkinson et al, 1992).
The transcriptional effects of retinoids are mediated by their
interactions with RARs (Giguere et al, 1987; Petkovich et al,
1987; Brand et al, 1988; Krust et al, 1989) and RXRs (retinoid
receptors) (Mangelsdorf et al, 1990; Mangelsdorf et al, 1992)
which are members ofthe steroid-thyroid hormone superfamily of
nuclear receptors. The RARs bind all-trans-RA and its stereoiso-
mers 9-cis-RA and 13-cis-RA (Allenby et al, 1993). The RXRs
differ from RARs in that they are incapable of binding all-trans-
RA and 13-cis-RA, but they bind and are activated by 9-cis-RA
(Heyman et al, 1992; Levin et al, 1992). Both RARs and RXRs
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bind as homo- orheterodimers to responsive elements in the DNA,
thereby acting as ligand-activated transcription factors. Apart from
the nuclear receptors, low molecular weight retinoic acid-binding
proteins exist (CRABPs). Theirprimary function is supposed to be
the regulation of the availability of retinoic acid for the nuclear
receptors by acting as a 'trap' (Napoli, 1993). They may also have
a shuttle function, transporting retinoids from the cytosol to the
nucleus (Leid et al, 1992). In spite of these apparently important
functions, recent data have shown that CRABP-I and CRABP-II
null mutant mice are essentially indistinguishable from wild-type
mice, as judged by their normal development, fertility, life span
and general behaviour, with the exception ofa minor limb malfor-
mation (Lampron et al, 1995).
Probably because of its potent physiological activity, retinoic
acid is subject to various catabolic transformations (Frolik et al,
1979; Sietsema and De Luca, 1982; Kraft et al, 1991). A primary
route by which retinoic acid is catabolized consists of a
cytochrome P450-dependent hydroxylation to form 4-hydroxy-
RA, which is further oxidized to 4-keto-RA and more polar
metabolites (Roberts et al, 1980). While the metabolites
4-hydroxy-RA (Williams et al, 1987) and 4-keto-RA bind to the
RARs, they are about 2-10 times less potent than RA in stimu-
lating gene transcription (Duell et al, 1992).
CRABP may play an important role in all-trans-RA catabolism.
Indeed, binding of all-trans-RA to CRABP decreases the elimina-
tion half-life ofall-trans-RA, which suggests that holo-CRABP is
a substrate with a lower Km value in all-trans-RA catabolism
(Fiorella and Napoli, 1991).
Oxidative retinoic acid catabolism mainly occurs in the liver and
to a lesser extent in other tissues, such as the skin (Vanden Bossche
1098Oxidative catabolism of RA in MCF-7 cells 1099
and Willemsens, 1990; Varani et al, 1991). Retinoic acid catabolism
has also been shown in N-methyl-N-nitrosourea-induced mammary
tumours in the rat(Bhat andLacroix, 1989), F9 teratocarcinoma cells
(Williams and Napoli, 1985) and LLC-PK1 cells (Napoli, 1986).
Recently all-trans-RA catabolism was further demonstrated in MCF-
7 breast cancer cells (Wouters et al, 1992) and rat Dunning R3327G
prostate tumour homogenates (Krekels et al, 1995). In vivo catabol-
ism of all-trans-RA has been extensively documented in rodents
(Hanni etal, 1976; Hanni andBigler, 1977; Frolik etal, 1980).
Liarozole-fumarate, a new imidazole derivative with antitumoral
properties, inhibits the cytochrome P450-dependent catabolism of
all-trans-RA (Van Wauwe et al, 1990, De Coster et al, 1992;
Krekels et al, 1995). In vivo, this results in an increased plasma
half-life of all-trans-RA and in retinoid-mimetic effects (Van
Wauwe et al, 1992). The antitumoral effect of liarozole-fumarate
hasbeen provenexperimentally inprostate cancermodels (Dijkman
et al, 1994; Smets et al, 1995) and in prostate cancer patients
(Mahler etal, 1993). Liarozole-fumarate ispresently inphase III of
clinicaldevelopment for the treatment ofrelapsed prostate cancer.
Because of the various biological effects of all-trans-RA, all-
trans-RA catabolism can be considered an important pharmaco-
logical target. In patients with acute promyelocytic leukaemia
(APL), continuous oraldosing with all-trans-RA is associated with
aprogressive decrease inplasmadrug concentrations(Muindi etal,
1992), suggesting that all-trans-RA induces its own catabolism.
However, information on the induction ofall-trans-RA catabolism
in tumours or tumour cells islacking (Han and Choi, 1996). In this
article, we describe the induction ofthe oxidative catabolism ofall-
trans-RAby different retinoids in MCF-7 cells and further charac-
terize the inducedpathwayby its sensitivity to inhibitors.
MATERIALS AND METHODS
Drugs and chemicals
Liarozole-fumarate {5-[3(chlorophenyl)(lH-imidazole-l-yl)methyl]-
IH-benzimidazole (E)-2-butenedioate(2:3)}, synthesized at the
Janssen Research Foundation (Beerse, Belgium), was dissolved at
a concentration of 10-2 M in ethanol. All-trans-retinoic acid was
obtained from Serva (Heidelberg, Germany). 4-Keto-all-trans-
retinoic acid, 4-keto-13-cis-retinoic acid and 9-cis-retinoic acid were
a generous gift from Hoffmann-La-Roche (Basle, Switzerland).
CH55 ((E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxo-l-propenyl]benzoic
acid) was obtained through the generosity of Dr Shudo (Tokyo,
Japan). All the retinoids described above were dissolved at an initial
concentration of 4 x 10-3 M in ethanol. Retinol and 13-cis-retinoic
acid werepurchased fromEastman Kodak(Rochester,NY,USA) and
were dissolved at an initial concentration of 10-2 Min ethanol. [11,12-
3H(N)]All-trans-retinoic acid (1875.9 GBq mmol-1, 50.7 Ci mmol-1)
was obtained from NEN (Dupont de Nemours, Brussel, Belgium).
Retinoid stock solutions were regularly checked for purity using
high-performance liquid chromatography (HPLC) analysis. Further
dilutions of all compounds were made in culture medium or assay
medium. Final solvent concentrations during incubations were
always < 0.5% (v/v). Retinoid manipulations were carried out in a
dark room withyellow illumination. All otherchemicals and solvents
were ofthehighestpurity available.
Cell cultivation
The MCF-7 cell line was obtained from the American Type Culture
Collection (Rockville, MD, USA). Cells were routinely cultured as
adherent monolayers at 37°C in 5% carbon dioxide-95% air at
100% relative humidity in Falcon tissue culture flasks (Becton
Dickinson, Aalst, Belgium). The culture medium was Dulbecco's
modified Eagle medium with 4.5 g 1-l glucose and 3.7 g 1-l sodium
bicarbonate supplemented with 2 mm glutamine, 1 mm sodium
pyruvate, 50 [ig ml-' gentamycin and 10% fetal calf serum (all
reagents from Life Technologies, Gent, Belgium). Cells were
subcultured once weekly at a split ratio of 1:10 usingtrypsin/EDTA
solution and were regularly checked for mycoplasma contamina-
tion. For the experiments described in this study, the MCF-7 cell
line was used at passages between 169 and 194.
Retinoic acid catabolism
Semiconfluent MCF-7 cultures, growing under normal conditions,
were treated for different periods of time with various retinoids.
Cells were then washed twice with 25 ml of culture medium and
trypsinized. Using this procedure, all-trans-RA used during prein-
cubation was washed out. This was checked using radiolabelled
all-trans-RA (results not shown). Cells were resuspended at 4 x
106 cells ml-' in Dulbecco's modified Eagle medium without
phenol red, containing 1 g 1-' glucose and supplemented with
2 mm glutamine, 1 mm sodium pyruvate, 50 [tg ml-' gentamycin
and 10% heat-inactivated fetal calf serum (all reagents from Life
Technologies). Aliquots (450 tl) of this cell suspension were
preincubated for 5 min at 37°C with 25 p.l of retinoid, liarozole-
fumarate or the solvent in glass test tubes. Incubation was then
continued for 90 minin the presence of25 tl of[11,12--3H(N)]all-
trans-retinoic acid. At the end ofincubation, the reaction mixture
was analysed for retinoic acid metabolites using a quantitative
microcolumn assay or C,8 reversed-phase HPLC (for determina-
tion ofelution profiles).
Microcolumn assay for all-trans-RA catabolism
All-trans-RA catabolism was quantitatively determined using the
microcolumn assay described by Garrabrant and End (1995) with
minor modific.ations. Briefly, the reaction mixture was mixed with
2 ml of 100% acetonitrile. Aftercentrifugation for 10minat 780 g,
the resulting deproteinated supematant was acidified with 2.5 ml
of 40 mm acetic acid. The acidified liquid was applied to a 3-ml
C,8 Bond Elut LRC column (Sopar Biochem, Brussel, Belgium)
(pretreated with 20 ml of methanol followed by 4 ml of distilled
water) under a vacuum of 127 mmHg using a VAC ELUT SPS-24,
and the effluent (fraction 1) was collected. The column was then
eluted with 1 ml of 40% acetonitrile in water (fraction 2).
Fractions 1 and 2, containing the polar metabolites, were
combined. Finally, the column was eluted with 1.5 ml ofmethanol
containing 5 mg ml-' butylated hydroxyanisole (fraction 3). All
fractions were counted forradioactivity in a Packard Tri-carb 4530
liquid scintillation analyser. Optiphase 'Hi Safe II' (Packard) was
used as a scintillator.
HPLC analysis
Reversed-phase HPLC was carried out on a Varian liquid chro-
matograph equipped with a Perkin-Elmer ISS 100 automatic
injector, a UV-200 variable wavelength detector set at 350 nm and
a star 4.0 data system. Radioactivity in the eluate was monitored
on line by a-counting (Berthold LB 504 radioactivity monitor)
using Pico-Aqua (Canberra-Packard, Brussel, Belgium) as the
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Figure 1 Effect of all-trans-RA on induction of all-trans-RA catabolism in
MCF-7 cells. MCF-7 cells were preincubated for 24 h with different
concentrations of all-trans-RA. After the preincubation period, all-trans-RA
catabolism was determined using 10-7 M [3H]all-trans-RA. Results are
expressed as mean s.d. from three independent experiments performed in
duplicate. Untreated (= control) cells revealed all-trans-RA catabolism levels
of 1.48± 0.73 fmol polar RA metabolites 10 cells-' h-1
scintillation solvent. Samples were analysed using a 10-[tm
C,8 [iBondapak column (3.9 mm x 300 mm, Waters, Brussel,
Belgium). The reaction mixture was extracted with 2 ml of 100%
acetonitrile containing 0.05% butylated hydroxyanisole. After
centrifugation (10 min at 780 g), the deproteinated supernatant
was evaporated in vacuo (Savant Speed Vac Concentrator), and
the residue was redissolved in methanol-water-formic acid
(65:35:0.05). After application to the column, samples were eluted
with methanol-water-formic acid (65:35:0.05) containing 10 mM
ammonium acetate at a flow rate of 2 ml min-'. After 20 min, the
solvent was changed to 100% methanol to elute retinoic acid.
Northern blotting for CRABP-Il mRNA
MCF-7 cells were preincubated for 24 h with 10 6 and 10-7 Mall-
trans-RA. Total RNA was extracted from cells using Trisolv
(Biotecx Laboratories, Houston, TX, USA) as described by the
manufacturer. Equal amounts of RNA were size-fractionated by
electrophoresis in a 1.2% agarose (Pharmacia, Uppsala, Sweden)
gel, using glyoxal (Fluka Biochimica, Bucks, Switzerland) -
dimethyl sulphoxide (DMSO) as the denaturing system. After
electrophoresis, the RNA was transferred to a positively charged
nylon membrane (Zeta-probe, Biorad, Nazareth, Belgium) by
vacuum blotting under mild alkali conditions. The blot was prehy-
bridized in 12.5 ml of hybridization buffer [3 x standard sodium
citrate (SSC)/1% sodium dodecyl sulphate (SDS), 5 x Denhardt's,
0.1 mg ml-' herring sperm DNA] at 68°C for about 5 h.
Hybridization was carried out ovemight at 68°C using the same
buffer containing a radioactive probe. The human CRABP-1l
100-
00
Figure 2 All-trans-RA catabolism in MCF-7 cells after preincubation with
different retinoids. MCF-7 cells were preincubated for 24 h with different
concentrations of all-trans-RA, 9-cis-RA, 13-cis-RA, 4-keto-all-trans-RA,
4-keto-13-cis-RA, retinol or CH55 (13, 10M; N, 10-8M; *, 10-7M; 0, 106M;
E3, 1 M). After the preincubation period, all-trans-RA catabolism was
determined using 10-7 M [3H]all-trans-RA. All-trans-RA at 1 0- M was set as
the 100% control value. Results are expressed as mean s.d. from three
independent experiments performed in duplicate. Note the different
concentrations used for CH55
probe was a cDNA clone (924 bp) containing the complete coding
region for the mRNA and was obtained through the generosity
of Dr C Lau (Johnson & Johnson, Canada). The probe was
radioactively labelled by random priming using [a-32P]dCTP
(3000 Ci mmol-1; NEN, Dupont de Nemours, Dreieich, Germany).
Hybridized blots were washed briefly in 2 x SSC at room temper-
ature, once in 2 x SSC/1% SDS for 15 min at room temperature
and four times in 0.2 SSC/1% SDS at 680C for 20 min. The last
wash was done in 0.2 SSC/1% SDS at 680C for 150 min. The
washed blot was rinsed with 0.2 x SSC and autoradiographed at
-70°C with two intensifying screens for 1-3 days. After autoradi-
ography, the blot was stripped and rehybridized with a GAPDH
probe (Westburg, Leusden, The Netherlands), using the same
conditions as for CRABP-II hybridization. Quantification was
performed by optical densitometric scanning.
Data analysis
All experiments were performed at least three times and duplicate
values were obtained for each data point. Data are shown as mean
s.d. Lineweaver-Burk plots and IC50 values were calculated by
linear regression analysis.
RESULTS
Validation of the microcolumn method
Validation of the microcolumn method for use with MCF-7 cells
was performed according to Garrabrant and End (1995). Fractions
1 and 2 contained the polar metabolites and were free of
unchanged all-trans-RA as determined from HPLC analysis. The
intermediate polar all-trans-RA metabolites co-eluted with 4-OH-
all-trans-RA and 4-keto-all-trans-RA. The mixture of very polar
metabolites was not separated or identified. Fraction 3 was free of
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Figure 3 Time course of all-trans-RA catabolism induction by all-trans-RA.
MCF-7 cells were preincubated with 10-6M all-trans-RA for different time
periods up to 48 h (- o -) orfor 16 h followed by wash-out and further
incubation (- * -). Following these preincubations, all-trans-RA catabolism
was determined using 10-7 M [3H]all-trans-RA. Results are expressed as
mean ± s.d. from three independent experiments performed in duplicate
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Figure 5 Enzyme characteristics of induced all-trans-RA catabolism.
Representative Michaelis-Menten and Lineweaver-Burk plot (insert)
obtained with MCF-7 cells preincubated for 24 h with 1Q6 M all-trans-RA.
The substrate concentrations varied between 5 x 10 M and 10-6 M
[3HJall-trans-RA
Table 1 Effects of actinomycin D on induction of all-trans-RA catabolism in
MCF-7 cells
Actinomycin D RA catabolism
concentration (% of control)
0.01 ig ml-' 48.8 ± 2.9
0.1 gml- 14.3 9.5
1 g ml-' 11.7 6.6
MCF-7 cells were preincubated for 24 h with 10 6 M all-trans-RA in
combination with different concentrations of actinomycin D. After the
preincubation period, all-trans-RA catabolism was determined using 107 M
[3H]all-trans-RA as the substrate. Results are expressed as mean ± s.d. of
three experiments performed in duplicate.
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Figure 4 CRABP-II mRNA expression in MCF-7 cells. MCF-7 cells were
incubated with 10-6 M and 11- M all-trans-RA during 24 h and CRABP-11
mRNA was measured by Northern blotting. Lane 1,4: control; lane 2,5:
10-7 M all-trans-RA; lane 3,6: 10Q- M all-trans-RA. Lower part of the figure
shows GAPDH controls for equal loading
polar metabolites but contained unchanged all-trans-RA. The
percentage conversion of all-trans-RA to polar metabolites,
obtained using either the microcolumn method or HPLC analysis,
was identical. Therefore the microcolumn assay was used to quan-
tify all-trans-RA catabolism in MCF-7 cells (results not shown).
Induction of all-trans-RA catabolism
To induce all-trans-RA catabolism, MCF-7 cells were preincu-
bated for 24 h with varying concentrations of all-trans-RA, 9-cis-
RA, 13-cis-RA, 4-keto-all-trans-RA, 4-keto-13-cis-RA, retinol or
CH55. This preincubation did not decrease viability ofthe cells, as
determined using trypan blue (results not shown). After the pre-
incubation period, all-trans-RA catabolism was determined using
1O-7M [3H]all-trans-RA as the substrate. While MCF-7 cells
showed very low constitutive all-trans-RA catabolism, preincuba-
tion with all-trans-RA concentration-dependently induced all-
trans-RA catabolism (Figure 1). Significant induction was
obtained with 10-8 M all-trans-RA while maximal induction of
about 45-fold was seen with 10 M all-trans-RA (63.7 ± 5.1 fmol
polar RA metabolites 10 cells-' h-1).
Figure 2 summarizes the induction of [3H]all-trans-RA catabol-
ism observed with different retinoids. All-trans-RA was the most
active natural retinoidforinduction ofall-trans-RA catabolism. The
activity of 13-cis-RA was similar to that of all-trans-RA. The
natural retinoids retinol, 4-keto-all-trans-RA and 4-keto-13-cis-RA
were clearly less potent than all-trans-RA; 9-cis-RA showed inter-
mediate potency. CH55, a synthetic retinoid, was active in aconcen-
tration range two orders ofmagnitude higher than all-trans-RA.
Induction of [3H]all-trans-RA catabolism was time dependent
with a fast onset and maximal induction achieved after a preincu-
bation period of 16-24 h (Figure 3). Thereafter, the [3H]all-
trans-RA catabolism declined, in spite of continued presence of
all-trans-RA. To further examine this decline, MCF-7 cells
were maximally induced for 16 h with I06 M all-trans-RA. The
inducing retinoid was then washed away and all-trans-RA
catabolism was determined at different time periods using 10-7 M
[3H]all-trans-RA. All-trans-RA catabolism induction decreased
to the constitutive level within 24 h after the maximal induction
time and wash-out ofthe inducing retinoid (Figure 3).
Induction of all-trans-RA catabolism by all-trans-RA was
inhibited by actinomycin D (Table 1), showing that regulation
occurs at the transcriptional level.
Contribution of CRABP
To determine the possible contribution ofCRABP to the induction
of all-trans-RA catabolism, MCF-7 cells were incubated with
I06 M and I0-7 M all-trans-RA during 24 h, and CRABP mRNA
was measured by Northem blotting. Expression of CRABP-I
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Table 2 Inhibition of all-trans-RA catabolism
Compound IC50 value (>tM)
All-trans-RA 0.13 ± 0.05
9-cis-RA 1.89 + 0.44
13-cis-RA 0.75 ± 0.15
4-Keto-all-trans-RA 0.37 + 0.10
4-Keto-13-cis-RA 6.60 + 2.05
Retinol 7.34 ± 3.13
CH55 > 10
Liarozole-fumarate 0.44 ± 0.37
MCF-7 cells were preincubated for 24 h with 10- M all-trans-RA. IC50 values
for inhibition of all-trans-RA catabolism were measured using 10-7 M [3H]all-
trans-RA as the substrate. Results are expressed as mean ± s.d. from three
experiments performed in duplicate.
mRNA was very low in MCF-7 cells and remained low after treat-
ment with all-trans-RA (results not shown). CRABP-II mRNA
was expressed at much higher levels (Figure 4). Incubation with
all-trans-RA resulted in slightly decreased CRABP-II mRNA
levels with 10 M and 10-7 M all-trans-RA producing 42% and
20% reductions in CRABP-II mRNA respectively.
Characterization of induced all-trans-RA catabolism
After preincubation with I06 M all-trans-RA for 24 h, all-trans-
RA catabolism was determined with [3H]all-trans-RA as the
substrate at concentrations varying from 5 x 10-9 M to 106 M. Data
presented as Michaelis-Menten and Lineweaver-Burk plots are
shown in Figure 5. From three independent experiments, an esti-
mated K value of0.33 ± 0.15 1AM (mean ± s.d.) and a Vmax value of
54.5 ± 31.3 fmol polar RA metabolites 10 cells-1 h-1 (mean ± s.d.)
were obtained.
IC50 values for inhibition of all-trans-RA catabolism by
different retinoids and liarozole-fumarate were measured using
10-7 M [3H]all-trans-RA as the substrate. The results are shown in
Table 2. All-trans-RA was the most active compound with an IC50
value of 0.13 JiM. The synthetic retinoid CH55 (up to 10 FtM) did
not inhibit all-trans-RA catabolism. Retinol was the least active
natural compound. The activity of 13-cis-RA was 5 times less than
that ofall-trans-RA, and 9-cis-RA was about 15 times less active.
The metabolite 4-keto-13-cis-RA was about 50 times less
potent than all-trans-RA, while 4-keto-all-trans-RA showed
activity similar to that of all-trans-RA. Liarozole-fumarate inhib-
ited all-trans-RA catabolism with an IC50 value of0.44 J.M.
DISCUSSION
In cancer patients, treatment with all-trans-RA for extended
periods oftime is associated with a decrease in the plasma half-life
of the retinoid and eventually progressive disease. This decreased
half-life is believed to be due to enhanced cytochrome P450
activity (Miller et al, 1994). Enhanced P450-dependent all-trans-
RA catabolism following all-trans-RA treatment has also been
shown in cancer cell lines in vitro (Willams and Napoli, 1987;
Wouters et al, 1992). Little is known, however, about the nature of
this induction and the enzymatic characteristics of the ensuing
catabolism. Therefore we studied the induction of the oxidative
catabolism of all-trans-RA by different retinoids in MCF-7 cells
and examined the effects ofthe inhibitor liarozole-fumarate.
MCF-7 cells showed very low constitutive all-trans-RA
catabolism but this all-trans-RA catabolism could easily be
induced by preincubation with all-trans-RA. After induction to a
maximum level, the induced all-trans-RA catabolism declined in
continued presence of all-trans-RA. The rate of this post-
maximum decline was similar to that seen in cells that were maxi-
mally induced with all-trans-RA and from which the inducing
retinoic acid was subsequently washed away. This suggests that
the post-maximum decline in continued presence of all-trans-RA
was due to gradual lowering of all-trans-RA concentration or due
to the binding ofall-trans-RA to binding proteins and so yielding
less free all-trans-RA. Gradual lowering of all-trans-RA concen-
tration seems unlikely because of the low V value and relative
short time of incubation. In contrast to what has been repeatedly
described for the skin and for skin-derived cell cultures (Elder et
al, 1993), CRABP-II was not inducedby all-trans-RA treatment in
MCF-7 cells. On the contrary, at high all-trans-RA concentrations,
even a slight decrease of CRABP-II mRNA was seen. Therefore,
lowering of all-trans-RA by enhanced binding to binding proteins
is also not an obvious explanation. Another explanation for the
decrease in metabolizing capacity in continued presence of
all-trans-RA could be down-regulation of the enzyme(s) involved
in catabolization as a consequence of the initial induction.
Unfortunately, this hypothesis could not be investigated because
neither the protein(s) itselfnor the gene encoding fortheprotein(s)
have yet been identified.
Enzyme kinetic studies of all-trans-RA-induced all-trans-RA
catabolism revealed an estimated Km value of0.33 FiM. As a whole
cell system is used, this estimated Km value reflects the uptake of
all-trans-RA by the cells, the transport of all-trans-RA through the
cells and the interactions of all-trans-RA with different cellular
structures and organelles and serum present in the culture medium.
Van Wauwe et al (1988) and Roberts et al (1980) reported Km
values of 12.5 FtM and 1.1 J.M, respectively, for hamster liver
microsomes. In rat Dunning R3327G tumour homogenates and rat
liver homogenates Km values of 1.7 JiM and 4.3 JtM were found. It
is not clear whether these different Km values reflect real differ-
ences in affinity for all-trans-RA between human and rodent
4-hydroxylase. The conversion of all-trans-RA to polar metabo-
lites was probably catalysed by more than one P450-dependent
enzyme (Van Wauwe et al, 1994). The nature of the enzyme(s) is
unknown. Therefore, the kinetic parameters reported in this manu-
script represent the overall formation ofpolar metabolites from all-
trans-RA and may not represent the kinetics for a single enzyme.
Different retinoids were compared for their potency to induce
all-trans-RA catabolism. The activity declined in the following
order: CH55 > all-trans-RA, 13-cis-RA > 4-keto-all-trans-RA,
4-keto-13-cis-RA, retinol> 9-cis-RA. Interpretation ofthese data is
complicated by the fact that the induction obtained for the different
RA isomers did not only result from the intact retinoid but was also
influenced by metabolites and different isomers. Indeed, formation
of polar RA metabolites increased with increasing incubation time.
Moreover, from experiments we previously have performed that are
not described in this paper, it became clear that limited isomeriza-
tion among the different retinoids also occurred. All-trans-RA and
9-cis-RA were found to isomerize to each other and to 13-cis-RA.
A di-cis-RA metabolite was also formed. 13-cis-RA only isomer-
ized to all-trans-RA. Retinol, on the other hand, was not converted
to RA; it was primarily oxidatively metabolized.
With the exception of 9-cis-RA, the potencies of the different
retinoids for inducing RA catabolism resemble those previously
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reported for other biological effects. In HL-60 leukaemia cells
all-trans-RA and 13-cis-RA were equipotent in inducing differen-
tiation; 9-cis-RA was reported to be equipotent to 10-fold as active
as all-trans-RA in inducing cell differentiation (Bollag and
Holdener, 1992; Matsushima et al, 1992). Our data, on the other
hand, show that 9-cis-RA is less active than all-trans-RA. In F9
embryonal carcinoma cells, retinol was approximately 10% as
active as all-trans-RA in inducing differentiation (Willams and
Napoli, 1985). In the clonal rhabdomyosarcoma cell line, BA-
HAN-IC, the metabolites 4-keto-all-trans-RA and 4-hydroxy-all-
trans-RA exhibited differentiation-inducing activity that was
significantly weaker than the inducing activity of all-trans-RA
(Ramp et al, 1994). In RbTE cells and HL-60 leukaemia cells, the
biological activity ofthe synthetic retinoid CH55 was much higher
(20-25 times) than that of all-trans-RA (Jetten et al, 1987).
Overall, the RA catabolism-inducing capacity of the different
retinoids correlates with the retinoic acid receptor binding affini-
ties of the retinoids (Crettaz et al, 1990; Sani et al, 1990; Repa et
al, 1993; Berggren Soderhund et al, 1995), suggesting that induc-
tion of RA catabolism is a receptor-mediated process. Two other
lines of evidence substantiate this idea. MCF-7 cells treated with
106 M and 10-7 M all-trans-RA for 24 h showed slightly decreased
CRABP-II mRNA levels in comparison to untreated cells.
Induction of RA catabolism, therefore, cannot be the result of
more all-trans-RA bound to CRABP and the 'catalyst' function
ascribed to this binding. Secondly, induction of catabolism was
inhibited by actinomycin D, indicating a transcriptional event.
Therefore, preincubation with retinoids does not stabilize or acti-
vate the metabolizing enzyme molecules already present. Rather,
transcription of the gene(s) for this enzyme(s) was required. The
final proof for the involvement ofretinoic acid receptor-mediated
induction would of course be demonstration of a RARE (retinoic
acid responsive element) sequence in the promotor region of the
gene(s) coding for the cytochrome P450 involved in RA catabol-
ism. Until now, however, the gene(s) has not been cloned and the
exact P450 isozyme(s) responsible for this important metabolic
pathway is unknown.
Pharmacological characterization of inhibition of RA catabol-
ism was also performed. The different RA isomers all inhibited
this reaction with decreasing activity in the order: all-trans-RA >
13-cis-RA > 9-cis-RA. Oxidation ofthe retinoids in the 4-position
led to a decrease in activity that was more pronounced for 13-cis-
RA than forall-trans-RA. Retinol was only a weak inhibitor ofRA
catabolism. This is somewhat surprising as one ofthe major path-
ways for oxidative catabolism of retinol is via 4-hydroxylation
(Leo and Lieber, 1985). This could mean that RA is a better
substrate for this enzyme than retinol or, alternatively, that each
retinoid is 4-hydroxylated by different P450 (iso)enzymes. The
biologically very active, synthetic retinoid CH55 did not inhibit
RA catabolism at all. The activity ofliarozole-fumarate (0.44 [tM)
was only slightly lower than that of all-trans-RA. This IC50 value
is similar to those reported previously for liarozole-fumarate in rat
Dunning R3327G tumour homogenates (0.26 FtM) and rat liver
homogenates (0.14 [tM) (Krekels et al, 1995). Taken together, the
results presented here show that all-trans-RA catabolism can be
induced by natural as well as synthetic retinoids and that induction
is a receptor-mediated process. The induced metabolism can be
inhibited by several retinoids, including the 13-cis and 9-cis
isomers ofRA. The data further illustrate an importantdifficulty in
using RA for in vitro work. Unresponsiveness ofcells towards RA
may be the consequence of induced RA catabolism, especially
during long-term experiments. Finally, this study also confirms
liarozole-fumarate as an active inhibitor of all-trans-RA catabo-
lism not only in the liverbut also in tumourcells. This inhibition is
thought to underlie the antitumoral properties of liarozole-
fumarate, which is currently under clinical investigation.
ABBREVIATIONS
RA, retinoic acid; CRABP, cytosolic retinoic acid-binding protein;
Km, Michaelis-Menten constant; VmaX maximal velocity of an
enzyme-catalysed reaction; RAR and RXR, retinoid receptors;
PSA, prostate-specific antigen; APL, acute promyelocytic
leukaemia; dCTP, deoxycytidine triphosphate; GAPDH, glycer-
aldehyde phosphate dehydrogenase; RARE, retinoic acid respon-
sive element; SSC, standard sodium citrate.
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